Inotek Pharmaceuticals Corporation Company Profile (NASDAQ:ITEK)

About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)

Inotek Pharmaceuticals Corporation logoInotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ITEK
  • CUSIP: N/A
  • Web: www.inotekpharma.com
Capitalization:
  • Market Cap: $41.87 million
  • Outstanding Shares: 27,010,000
Average Prices:
  • 50 Day Moving Avg: $1.04
  • 200 Day Moving Avg: $1.53
  • 52 Week Range: $0.85 - $9.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.13 per share
  • Price / Book: 0.73
Profitability:
  • EBIDTA: ($38,560,000.00)
  • Return on Equity: -59.26%
  • Return on Assets: -33.15%
Debt:
  • Debt-to-Equity Ratio: 0.86%
  • Current Ratio: 27.39%
  • Quick Ratio: 27.39%
Misc:
  • Average Volume: 1.22 million shs.
  • Beta: 2.76
  • Short Ratio: 1.58
 

Frequently Asked Questions for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)

What is Inotek Pharmaceuticals Corporation's stock symbol?

Inotek Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "ITEK."

How were Inotek Pharmaceuticals Corporation's earnings last quarter?

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) released its earnings results on Thursday, August, 3rd. The company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.23. View Inotek Pharmaceuticals Corporation's Earnings History.

When will Inotek Pharmaceuticals Corporation make its next earnings announcement?

Inotek Pharmaceuticals Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Inotek Pharmaceuticals Corporation.

Where is Inotek Pharmaceuticals Corporation's stock going? Where will Inotek Pharmaceuticals Corporation's stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for Inotek Pharmaceuticals Corporation's shares. Their predictions range from $2.00 to $10.00. On average, they anticipate Inotek Pharmaceuticals Corporation's stock price to reach $4.50 in the next year. View Analyst Ratings for Inotek Pharmaceuticals Corporation.

What are analysts saying about Inotek Pharmaceuticals Corporation stock?

Here are some recent quotes from research analysts about Inotek Pharmaceuticals Corporation stock:

  • 1. According to Zacks Investment Research, "Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts. " (9/12/2017)
  • 2. HC Wainwright analysts commented, "Phase 2 FDC data release narrowed to July. With the timing of Inotek’s Phase 2 fixed-dose combination (FDC) trial readout nearing, the company issued a release refining that window from mid-2017 to July, as enrollment for the study has now been completed. The market is not expecting a lot after the MATrX-1 study failed to beat placebo in January, but there is still a glimmer of hope for a positive outcome. Given the company’s enterprise value of negative $27M, we see a much stronger case for the upside (potential confirmation of efficacy with the more valuable, in our view, FDC product) versus limited downside." (4/12/2017)

Who are some of Inotek Pharmaceuticals Corporation's key competitors?

Who are Inotek Pharmaceuticals Corporation's key executives?

Inotek Pharmaceuticals Corporation's management team includes the folowing people:

  • J. Martin Carroll, Independent Chairman of the Board
  • David P. Southwell, President, Chief Executive Officer, Director
  • Dale Ritter, Vice President—Finance, Principal Financial and Accounting Officer, Treasurer, Secretary
  • Rudolf A. Baumgartner M.D., Executive Vice President, Chief Medical Officer
  • Timothy Joseph Barberich, Independent Director
  • Carsten Boess, Independent Director
  • Paul G. Howes, Independent Director
  • Patrick Machado J.D., Independent Director
  • Gary M. Phillips M.D., Independent Director

When did Inotek Pharmaceuticals Corporation IPO?

(ITEK) raised $40 million in an initial public offering on Wednesday, February 18th 2015. The company issued 6,700,000 shares at $6.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Nomura were co-managers.

Who owns Inotek Pharmaceuticals Corporation stock?

Inotek Pharmaceuticals Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include RHO Capital Partners Inc. (9.74%), Senzar Asset Management LLC (3.13%), Sphera Funds Management LTD. (1.49%), Columbus Circle Investors (1.41%), Vanguard Group Inc. (1.17%) and Goldman Sachs Group Inc. (0.64%). Company insiders that own Inotek Pharmaceuticals Corporation stock include David P Southwell and J Martin Carroll. View Institutional Ownership Trends for Inotek Pharmaceuticals Corporation.

Who sold Inotek Pharmaceuticals Corporation stock? Who is selling Inotek Pharmaceuticals Corporation stock?

Inotek Pharmaceuticals Corporation's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Senzar Asset Management LLC and Columbus Circle Investors. View Insider Buying and Selling for Inotek Pharmaceuticals Corporation.

Who bought Inotek Pharmaceuticals Corporation stock? Who is buying Inotek Pharmaceuticals Corporation stock?

Inotek Pharmaceuticals Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., LMR Partners LLP and GSA Capital Partners LLP. Company insiders that have bought Inotek Pharmaceuticals Corporation stock in the last two years include David P Southwell and J Martin Carroll. View Insider Buying and Selling for Inotek Pharmaceuticals Corporation.

How do I buy Inotek Pharmaceuticals Corporation stock?

Shares of Inotek Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inotek Pharmaceuticals Corporation's stock price today?

One share of Inotek Pharmaceuticals Corporation stock can currently be purchased for approximately $1.55.


MarketBeat Community Rating for Inotek Pharmaceuticals Corporation (NASDAQ ITEK)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Inotek Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $4.50 (190.32% upside)

Analysts' Ratings History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/12/2017Canaccord GenuityDowngradeBuy -> HoldMediumView Rating Details
7/11/2017HC WainwrightDowngradeBuy -> Neutral$2.00HighView Rating Details
1/3/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$3.00N/AView Rating Details
12/1/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Earnings by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Earnings History by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ ITEK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017        
8/3/2017Q2 2017($0.47)($0.24)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.39)($0.40)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.43)($0.48)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.45)($0.41)ViewN/AView Earnings Details
8/10/2016Q2($0.40)($0.33)ViewN/AView Earnings Details
5/11/2016Q1($0.22)($0.38)ViewN/AView Earnings Details
3/23/2016Q4($0.37)($0.13)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.29)($0.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
2017 EPS Consensus Estimate: ($1.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.31)($0.31)($0.31)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Insider Ownership Percentage: 11.70%
Institutional Ownership Percentage: 29.16%
Insider Trades by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Institutional Ownership by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Insider Trades by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2017David P. SouthwellInsiderBuy60,000$1.75$105,000.00View SEC Filing  
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.00View SEC Filing  
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00View SEC Filing  
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Latest Headlines for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Source:
DateHeadline
finance.yahoo.com logoIs It The Right Time To Buy Inotek Pharmaceuticals Corporation (ITEK)?
finance.yahoo.com - September 22 at 1:41 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and 22nd Century Group
finance.yahoo.com - September 15 at 2:19 AM
streetinsider.com logoInotek Pharma (ITEK) to Merge with Rocket Pharmaceuticals - StreetInsider.com
www.streetinsider.com - September 14 at 6:36 AM
americanbankingnews.com logoZacks Investment Research Lowers Inotek Pharmaceuticals Corp (ITEK) to Hold
www.americanbankingnews.com - September 12 at 11:56 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) versus Applied Genetic Technologies Corporation (AGTC) Financial Analysis
www.americanbankingnews.com - September 12 at 8:28 PM
finance.yahoo.com logoInotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
finance.yahoo.com - September 12 at 4:51 PM
americanbankingnews.com logoIgnyta (RXDX) and Inotek Pharmaceuticals Corporation (ITEK) Head-To-Head Survey
www.americanbankingnews.com - September 4 at 2:12 AM
streetinsider.com logoVasuda Capital Management Seeks to Inspects Books and Records ... - StreetInsider.com
www.streetinsider.com - September 2 at 6:53 PM
streetinsider.com logoVasuda Capital Management Seeks to Inspects Books and Records of Inotek Pharmaceuticals (ITEK) Related to Potential Sale
www.streetinsider.com - August 31 at 8:02 PM
seekingalpha.com logoInotek: No Products, No Pipeline, No Problem - Seeking Alpha
seekingalpha.com - August 20 at 7:14 PM
americanbankingnews.com logoInotek Pharmaceuticals Corporation (ITEK) Posts Quarterly Earnings Results, Beats Expectations By $0.23 EPS
www.americanbankingnews.com - August 4 at 5:46 PM
businesswire.com logoInotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights - Business Wire (press release)
www.businesswire.com - August 3 at 8:11 PM
finance.yahoo.com logoInotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - August 3 at 8:11 PM
finance.yahoo.com logoInotek Pharmaceuticals reports 2Q loss
finance.yahoo.com - August 3 at 8:11 PM
seekingalpha.com logoAfter Another Clinical Failure, Is Inotek Dead Money? - Seeking Alpha
seekingalpha.com - July 18 at 4:54 PM
americanbankingnews.com logoInotek Pharmaceuticals Corporation (ITEK) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 14 at 11:02 PM
americanbankingnews.com logoInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Downgraded by HC Wainwright to "Neutral"
www.americanbankingnews.com - July 11 at 7:50 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Ocular Therapeutix and Inotek Pharmaceuticals
finance.yahoo.com - July 10 at 7:59 PM
nasdaq.com logoInotek shares plunge after sole eye drug fails another trial
www.nasdaq.com - July 8 at 11:52 AM
finance.yahoo.com logoInotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update
finance.yahoo.com - July 8 at 11:52 AM
finance.yahoo.com logoInotek to consider strategic options after eye drug fails another study
finance.yahoo.com - July 8 at 11:52 AM
finance.yahoo.com logoLexington’s Inotek suggests it could explore sale after another trial flop
finance.yahoo.com - July 8 at 11:52 AM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Inotek Pharmaceuticals (ITEK) Stock
finance.yahoo.com - July 7 at 6:35 AM
americanbankingnews.com logoInotek Pharmaceuticals Corporation (ITEK) Expected to Announce Earnings of -$0.50 Per Share
www.americanbankingnews.com - June 22 at 7:42 AM
seekingalpha.com logoInotek Pharmaceuticals Is A Strong Buy Before Phase II Data In July - Seeking Alpha
seekingalpha.com - June 13 at 5:48 PM
americanbankingnews.com logo-$0.47 Earnings Per Share Expected for Inotek Pharmaceuticals Corp (ITEK) This Quarter
www.americanbankingnews.com - May 29 at 9:46 AM
americanbankingnews.com logoHC Wainwright Reiterates Buy Rating for Inotek Pharmaceuticals Corp (ITEK)
www.americanbankingnews.com - May 12 at 4:05 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 11 at 7:52 PM
finance.yahoo.com logoInotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - May 10 at 6:14 PM
businesswire.com logoInotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and ... - Business Wire (press release)
www.businesswire.com - May 10 at 1:14 PM
marketbeat.com logoInotek Pharmaceuticals reports 1Q loss
marketbeat.com - May 10 at 7:28 AM
finance.yahoo.com logoInotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting
finance.yahoo.com - May 8 at 5:38 PM
americanbankingnews.com logo-$0.35 Earnings Per Share Expected for Inotek Pharmaceuticals Corp (ITEK) This Quarter
www.americanbankingnews.com - May 3 at 4:08 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Earning Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 3 at 10:44 AM
finance.yahoo.com logoKalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook
finance.yahoo.com - May 2 at 10:38 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Earns Media Impact Score of -0.12
www.americanbankingnews.com - April 30 at 11:39 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Given Daily News Impact Rating of 0.19
www.americanbankingnews.com - April 28 at 12:10 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Given Daily Media Sentiment Score of 0.37
www.americanbankingnews.com - April 23 at 4:21 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Getting Positive News Coverage, Report Shows
www.americanbankingnews.com - April 20 at 11:51 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Receiving Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 14 at 12:48 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - April 12 at 4:36 PM
finance.yahoo.com logoBlog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
finance.yahoo.com - April 12 at 8:59 AM
finance.yahoo.com logoInotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost
finance.yahoo.com - April 11 at 11:48 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 11 at 9:57 AM
finance.yahoo.com logoInotek Pharmaceuticals Financial Review Potential Value Drivers and Drug Pipeline
finance.yahoo.com - April 7 at 10:31 AM
americanbankingnews.com logo Inotek Pharmaceuticals Corp (ITEK) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - April 4 at 12:28 AM
finance.yahoo.com logoINOTEK PHARMACEUTICALS CORP Financials
finance.yahoo.com - March 22 at 6:11 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Given a $3.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 22 at 10:41 AM
seekingalpha.com logoInotek Pharmaceuticals Could Be Getting A Second Chance
seekingalpha.com - March 21 at 5:58 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) PT Set at $3.00 by Canaccord Genuity
www.americanbankingnews.com - March 18 at 12:10 PM

Social

Chart

Inotek Pharmaceuticals Corporation (ITEK) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff